Pathway Methotrexate Pathway (Cancer Cell), Pharmacodynamics

Methotrexate cellular disposition and effects.
Methotrexate Pathway (Cancer Cell), Pharmacodynamics
clickable pathway icons

Description

Methotrexate (MTX) is a folate analogue that is used in the treatment of cancers (e.g., acute lymphoblastic leukemia, non-Hodgkin lymphoma, osteosarcoma, and colon cancer) and autoimmune diseases (e.g., rheumatoid arthritis, Crohn's disease, and psoriasis). In the treatment of autoimmune diseases, MTX is usually administrated orally or subcutaneously, whereas in cancer treatment, it can be given orally, intramuscularly, as intrathecal injections, or as intravenous infusions [Article:19858780; 19553647; 15139068]. The pharmacokinetics and pharmacodynamics of MTX show large interpatient variability regardless of the route of administration or disease being treated [Article:19901119; 20418240; 10912573]. This figure illustrates the candidate genes in the MTX pathway.

The pharmacodynamic profile of MTX can to a large extent be explained by its interactions with enzymes in the folate pathway. The effects on MTX response of variations in these genes have been extensively studied in cancer treatments [Article:19538530]. At extracellular MTX concentrations below 20┬ÁM, MTX enters cancer cells primarily via the reduced folate carrier (SLC19A1)[Article:10029593; 9748136], whereas efflux across the cell membrane is mediated by various ABC transporters; variations in these genes are known mechanisms of drug resistance in cancer cells [Article:16362298]. Inside the cells, MTX is converted to active methotrexate polyglutamates (MTXPGs) by folylpolyglutamate synthetase (FPGS), which adds glutamate residues to MTX [Article:7517720]. The primary action of MTX is inhibition of the enzyme dihydrofolate reductase (DHFR), which converts dihydrofolate (DHF) to tetrahydrofolate (THF)[Article:8793930]. THF is essential for de novo purine synthesis, and in the biologically active form, 5-methyl-THF, it is an important cofactor in one-carbon metabolism. The effect of MTX depends on the function and expression of several other enzymes in the folate pathway, including methylenetetrahydrofolate dehydrogenase (MTHFD1), 5,10-methylenetetrahydrofolate reductase (MTHFR), and thymidylate synthetase (TYMS). Compared with MTX, the active metabolites MTXPGs induce stronger inhibition of the target enzymes (i.e., TYMS and DHFR) and further inhibit key enzymes such as GART and ATIC in the de novo purine synthesis pathway. The inhibition by MTXPG results in decreased protein and DNA methylation in addition to impaired DNA formation and repair. MTXPG levels are sustained inside the cells for a longer time than those of MTX; degradation of MTXPGs to MTX depends on the activity of the lysosomal enzyme GGH, which catalyzes the removal of polyglutamates [Article:12114448; 16041371; 16826517]. MTXPGs have been investigated in relation to clinical outcomes in Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA). Specifically, higher concentrations of long chain MTXPGs have been associated with favourable outcomes in RA [Article:15457444] and risk of gastrointestinal and hepatic toxicity in JIA [Article:20954192].

Gene expression and genetic variation in candidate genes have been studied extensively in relation to many MTX response measures, including MTXPG accumulation (GGH, FPGS, and SLC19A1) [Article:10029593; 15284538; 15630450], reduction in tumor size (SLC19A1 and DHFR) [Article:10100715], toxicity (MTHFR, and TYMS) [Article:11418485; 16501586], and relapse (DHFR, TYMS, MTHFR, DHFR, and SLC19A1) [Article:19515727; 18096764; 20335220; 16130010; 14647408; 12411325; 15713801]. Conflicting results among studies suggest that the effects of genetic variation are therapy-dependent and probably reflect the route of administration, dose, and duration of MTX treatment [Article:20335220; 12411325]. Although these studies have contributed to our understanding of MTX's effects and the molecular mechanisms involved in drug resistance, no genetic variant has yet been prospectively evaluated as a predictor of outcome in a clinical trial.

Genome-wide studies have linked genes outside the folate pathway to the pharmacokinetics and effects of MTX; many of these genes have not previously been analyzed in studies using the candidate approach. A recent study analyzed the association between MTXPG accumulation and genetic variations such as leukemic cell gene expression, somatic copy number variation, and SNPs [Article:19066393]. Six genes on chromosome 18 (FHOD3, IMPA2, ME2, SLC39A6, SMAD2, and SMAD4) and one on chromosome 10 (RASSF4) were found to be associated with in vivo intracellular accumulation of MTXPG in leukemic cells in all three categories of genetic variation. In another genome-wide study of patients with acute lymphoblastic leukemia, in vivo response to MTX was found to be significantly associated with expression of genes in the nucleotide pathway (e.g., TYMS) but also with genes involved in cell proliferation and apoptosis, as well as DNA repair and replication in the leukemic cells [Article:18416598]. Finally, a genome-wide association study that assessed the link between inherited genomic variation and initial treatment response in patients with acute lymphoblastic leukemia revealed 14 SNPs significantly associated with both treatment response and MTX clearance or MTXPG accumulation in leukemic cells [Article:19176441]; early treatment response assessed by eradication of leukemic cells is strongly associated with cure rates and is therefore considered an important clinical phenotype.

No genome-wide association studies have yet been performed in patients with rheumatoid arthritis, but inherited variations in most genes from the folate pathway have been examined in relation to MTX treatment response and toxicity PMID :18381794; 16572443. However, to see a clinically relevant effect of genetic variants in the folate, purine, and pyrimidine pathways, it seems crucial to study gene-gene interactions; it has been suggested that the effects of individual SNPs are enhanced when they occur in combination with other common SNPs in these pathways [Article:19858780]. Combinations of SNPs in the genes ATIC and Adenosine Receptor 2a (ADORA 2a) have been associated with differential MTXPG concentrations in JIA (PMID :20954192). The anti-inflammatory effect of MTX is further thought to be mediated through interaction with the adenosine biosynthesis pathway [Article:12106498]. MTXPGs inhibit the enzyme ATIC, which after a cascade of events leads to accumulation of the anti-inflammatory molecule adenosine; SNPs in genes from the adenosine biosynthesis pathway (i.e., ATIC, ITPA, and AMPD1) have been found to predict the efficacy of MTX treatment of RA and JIA [Article:19858780; 16947783;17530705].

Regardless of disease, it seems clear that future studies should continue to examine the combined effect of variations in multiple genes to characterize the extent of genomic determinants on variation in the pharmacokinetics and pharmacodynamics of MTX.

Authors: Torben S. Mikkelsen, Caroline F. Thorn, Jun J. Yang, Cornelia M. Ulrich, Deborah French, Gianluigi Zaza, Henry M. Dunnenberger, Sharon Marsh, Howard L. McLeod, Kathy Giacomini, Mara L. Becker, Roger Gaedigk, J. Steven Leeder, Leo Kager , Mary V. Relling, William Evans..
Citation:
Mikkelsen Torben S, Thorn Caroline F, Yang Jun J, Ulrich Cornelia M, French Deborah, Zaza Gianluigi, Dunnenberger Henry M, Marsh Sharon, McLeod Howard L, Giacomini Kathy, Becker Mara L, Gaedigk Roger, Leeder James Steven, Kager Leo, Relling Mary V, Evans William, Klein Teri E, Altman Russ B. "PharmGKB summary: methotrexate pathway" Pharmacogenetics and genomics (2011).
If you would like to reproduce this PharmGKB pathway diagram, please acknowledge the copyright to PharmGKB and state that permission has been given by PharmGKB and Stanford University. Also, please send a brief email to feedback@pharmgkb.org to inform us of which pathway diagram you are using and for what purpose.
History:
Therapeutic Categories:
  • Anticancer agents

Entities in the Pathway

Genes (15)

Drugs/Drug Classes (1)

Relationships in the Pathway

Arrow FromArrow ToControllersPMID
5,10-methylenetrahydrofolate 5,10-methyltetrahydrofolate MTHFD1 14647408, 19812215
5,10-methylenetrahydrofolate 5-methyl tetrahyrofolate MTHFR 14647408, 15797993, 19812215
5,10-methylenetrahydrofolate dihydrofolate TYMS 11986237, 12084458, 12604405, 19812215, 19902562
5,10-methyltetrahydrofolate 10-formyltetrahydrofolate MTHFD1 14647408, 19812215
5-formyltetrahydrofolate 5,10-methyltetrahydrofolate MTHFS 19812215, 3801490
5-methyl tetrahyrofolate tetrahydrofolate cyanocobalamin, MTR, MTRR 19812215
IMP Black Box: de novo purine synthesis
ADA ADA ATIC, GART
adenosine inosine ADA 12106498
ADP ATP
AMP adenosine
AMP ADP
ATIC ATIC methotrexate polyglutamate (2 to 7)
DHFR DHFR methotrexate, methotrexate glutamate, methotrexate polyglutamate (2 to 7)
dihydrofolate tetrahydrofolate DHFR 12084458, 14529544, 19812215
dUMP dTMP TYMS
GART GART methotrexate polyglutamate (2 to 7)
glycine serine SHMT1 19812215
homocysteine cystathionine CBS 16013960, 19812215
homocysteine methionine cyanocobalamin, MTR, MTRR 15797993, 17611986, 19812215
IMP AMP
IMP inosine
inosine hypoxanthine
methionine S-adenosylmethionine 19812215
methotrexate glutamate methotrexate polyglutamate (2 to 7) FPGS 10029597, 12494465, 17875718, 19131550, 19902562
methotrexate polyglutamate (2 to 7) methotrexate polyglutamate (n-1 to 6) GGH 11389096, 14597182, 17286537, 17409534, 19827168
methotrexate polyglutamate (n-1 to 6) methotrexate glutamate
methotrexate methotrexate glutamate
MTHFR MTHFR S-adenosylmethionine
PPAT PPAT methotrexate polyglutamate (2 to 7)
S-adenosylhomocysteine homocysteine
S-adenosylmethionine S-adenosylhomocysteine 19812215
tetrahydrofolate 10-formyltetrahydrofolate MTHFD1 14647408, 19812215
tetrahydrofolate 5,10-methylenetrahydrofolate SHMT1 15797993, 19812215
TYMS TYMS methotrexate polyglutamate (2 to 7)

Download data in TSV format. Other formats are available on the Downloads/LinkOuts tab.